Literature DB >> 8422191

Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium.

L L Crussell-Porter1, J P Rindone, M A Ford, D W Jaskar.   

Abstract

BACKGROUND: Fluconazole has been reported to interact with many medications. This study examined the effect of low-dose fluconazole therapy on the hypoprothrombinemic response of warfarin sodium in patients.
METHODS: Patients receiving low-intensity anticoagulation therapy with warfarin were recruited. All patients were taking stable doses of warfarin and had two baseline prothrombin times (PTs) within 10% of each other. Each patient received 100 mg of fluconazole daily for 7 days. Prothrombin times were measured on days 2, 5, and 8 during fluconazole administration.
RESULTS: All patients had a progressive increase in PTs. Mean (+/- SD) of PTs increased from 15.8 +/- 1 seconds before the administration of fluconazole to 18.9 +/- 1.9 seconds on day 5 and 21.9 +/- 2.2 seconds on day 8. Fluconazole therapy was stopped early in the three patients due to high PTs. The largest change in PT was 9.7 seconds. No bleeding was noted during the study.
CONCLUSION: Fluconazole predictably potentiates the hypoprothrombinemic response of warfarin. Prothrombin times must be monitored when fluconazole is administered to patients taking warfarin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8422191

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  9 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 2.  Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.

Authors:  Romuald Bellmann; Piotr Smuszkiewicz
Journal:  Infection       Date:  2017-07-12       Impact factor: 3.553

Review 3.  Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions.

Authors:  Sara R Vazquez
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 4.  Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.

Authors:  Edith Nutescu; Ittiporn Chuatrisorn; Erika Hellenbart
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

Review 5.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

Review 6.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

Review 7.  Pharmacokinetic drug interactions with antimicrobial agents.

Authors:  J G Gillum; D S Israel; R E Polk
Journal:  Clin Pharmacokinet       Date:  1993-12       Impact factor: 6.447

Review 8.  The enzymatic basis of drug-drug interactions with systemic triazole antifungals.

Authors:  Yasmine Nivoix; Dominique Levêque; Raoul Herbrecht; Jean-Claude Koffel; Laurence Beretz; Genevieve Ubeaud-Sequier
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

9.  Evaluation of knowledge of Health care professionals on warfarin interactions with drug and herb medicinal in Central Saudi Arabia.

Authors:  Mohamed N Al-Arifi; Syed Wajid; Nawaf K Al-Manie; Faisal M Al-Saker; Salmeen D Babelgaith; Yousif A Asiri; Ibrahim Sales
Journal:  Pak J Med Sci       Date:  2016 Jan-Feb       Impact factor: 1.088

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.